Published in Endocr Rev on March 08, 2013
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH) | NCT00596934
What we talk about when we talk about fat. Cell (2014) 4.12
Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab (2013) 2.16
Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm (2013) 1.59
Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism (2014) 1.18
Irisin, two years later. Int J Endocrinol (2013) 0.97
Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab (2015) 0.94
Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes (Lond) (2013) 0.92
Leptin signaling. F1000Prime Rep (2014) 0.90
Leptin-induced endothelium-dependent vasorelaxation of peripheral arteries in lean and obese rats: role of nitric oxide and hydrogen sulfide. PLoS One (2014) 0.83
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol (2015) 0.83
Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes (2015) 0.82
Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci OA (2015) 0.81
Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr Metab (Lond) (2015) 0.80
Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine (2014) 0.79
Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration. Diabetes (2014) 0.78
Molecular Pathogenesis of NASH. Int J Mol Sci (2016) 0.78
Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy. Diabetes Care (2014) 0.78
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun Ageing (2015) 0.78
n-3 polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity-associated breast cancer. Nutrients (2014) 0.78
Subacute inhalation exposure to ozone induces systemic inflammation but not insulin resistance in a diabetic mouse model. Inhal Toxicol (2016) 0.76
Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev (2016) 0.75
Creosote Bush (Larrea tridentata) Improves Insulin Sensitivity and Reduces Plasma and Hepatic Lipids in Hamsters Fed a High Fat and Cholesterol Diet. Front Pharmacol (2016) 0.75
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (2004) 19.08
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 13.57
Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 13.05
Adipose tissue as an endocrine organ. J Clin Endocrinol Metab (2004) 11.94
Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (1995) 9.09
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature (2002) 8.77
Role of leptin in the neuroendocrine response to fasting. Nature (1996) 8.02
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Leptin-replacement therapy for lipodystrophy. N Engl J Med (2002) 7.78
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (1998) 7.36
Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (1997) 7.33
Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med (1999) 6.94
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med (2005) 6.49
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest (2002) 5.83
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature (1998) 5.75
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature (1999) 5.51
Long-term persistence of hormonal adaptations to weight loss. N Engl J Med (2011) 5.51
Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab (2009) 5.32
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A (1998) 4.72
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA (1999) 4.71
Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science (1996) 4.59
Lipotoxic diseases. Annu Rev Med (2002) 4.16
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology (2004) 4.10
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Leptin enters the brain by a saturable system independent of insulin. Peptides (1996) 3.97
Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell (1998) 3.84
A key role of leptin in the control of regulatory T cell proliferation. Immunity (2007) 3.71
Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest (2000) 3.50
Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab (1999) 3.26
Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A (2010) 3.23
Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007) 3.13
Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest (2005) 3.10
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest (2012) 2.98
Intracellular signalling pathways activated by leptin. Biochem J (2006) 2.93
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A (2011) 2.92
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta (2009) 2.84
Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab (2002) 2.76
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A (2008) 2.73
A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet (1998) 2.68
Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem (2003) 2.67
Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res (2004) 2.62
Leptin in immunology. J Immunol (2005) 2.62
Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab (2010) 2.58
Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab (2010) 2.58
Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A (2004) 2.57
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med (2007) 2.56
Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab (2005) 2.52
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 2.48
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A (2004) 2.41
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr (2007) 2.40
Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc Natl Acad Sci U S A (2004) 2.36
Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A (1999) 2.33
Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr (2007) 2.28
Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. J Immunol (2002) 2.27
Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology (2004) 2.22
Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab (2000) 2.19
Adipokines in liver diseases. Hepatology (2009) 2.14
Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest (2012) 2.12
Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A (2008) 2.12
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem (2008) 2.08
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med (1999) 2.05
Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab (2005) 2.04
Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med (2010) 2.00
Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem (2000) 1.99
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring) (2006) 1.92
Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest (2007) 1.91
Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes (2005) 1.89
Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab (2006) 1.88
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut (2010) 1.84
Partial leptin deficiency and human adiposity. Nature (2001) 1.83
Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci (2004) 1.81
Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest (2011) 1.80
Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest (2011) 1.80
Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes (1999) 1.79
Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A (2010) 1.79
Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab (2002) 1.78
Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia (2009) 1.75
Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J (2001) 1.72
Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest (2004) 1.71
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab (2006) 1.68
Leptin effects on pancreatic beta-cell gene expression and function. Diabetes (2004) 1.68
PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J Clin Invest (2010) 1.66
Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A (2010) 1.66
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology (2007) 1.64
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A (2009) 6.67
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism (2012) 3.61
Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation (2008) 3.56
Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation (2009) 3.47
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Adiponectin and breast cancer risk. J Clin Endocrinol Metab (2004) 2.72
Leptin in immunology. J Immunol (2005) 2.62
Pityriasis rosea-like eruption associated with lamotrigine. J Am Acad Dermatol (2013) 2.59
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care (2004) 2.55
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr (2007) 2.40
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab (2003) 2.25
Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr (2012) 2.23
Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr (2009) 2.22
Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab (2013) 2.16
Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab (2003) 2.09
Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 2.09
Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab (2007) 2.07
Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care (2007) 2.06
Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care (2007) 2.04
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med (2008) 2.01
Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med (2010) 2.00
Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care (2007) 1.99
Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab (2011) 1.99
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab (2006) 1.88
Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab (2004) 1.86
Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab (2003) 1.84
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism (2010) 1.81
Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab (2005) 1.81
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Leptin and reproduction: a review. Fertil Steril (2002) 1.68
Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab (2003) 1.65
Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut (2012) 1.65
Coffee drinking and risk of endometrial cancer--a population-based cohort study. Int J Cancer (2009) 1.63
Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res (2003) 1.62
Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology (2010) 1.62
Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab (2006) 1.61
Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab (2004) 1.61
Relationship of leptin to bone mineralization in children and adolescents. J Clin Endocrinol Metab (2003) 1.58
Neonatal leptin levels are strongly associated with female gender, birth length, IGF-I levels and formula feeding. Clin Endocrinol (Oxf) (2005) 1.57
Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology (2013) 1.57
Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab (2006) 1.55
Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet (2005) 1.55
Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab (2011) 1.55
Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care (2008) 1.51
Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration. J Clin Endocrinol Metab (2004) 1.51
Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism (2011) 1.51
Stable isotope tracer dilution for quantifying very low-density lipoprotein-triacylglycerol kinetics in man. Clin Nutr (2004) 1.49
Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab (2006) 1.47
Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci U S A (2006) 1.46
Leptin in human physiology and therapeutics. Front Neuroendocrinol (2010) 1.46
Helicobacter pylori may play a role in both obstructive sleep apnea and metabolic syndrome. Sleep Med (2011) 1.40
Association between Helicobacter pylori infection and fibromyalgia syndrome. Clin Rheumatol (2010) 1.40
Predictors of Circulating Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-Binding Protein-3 in Critical Illness. Crit Care Med (2015) 1.38
Helicobacter pylori-Related Impact on Glaucoma Pathophysiology. Invest Ophthalmol Vis Sci (2015) 1.38
Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev (2007) 1.37
Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes (2002) 1.37
Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) (2009) 1.37
Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol (2013) 1.37
Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes (2002) 1.37
Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism (2013) 1.36
Leptin in humans: lessons from translational research. Am J Clin Nutr (2009) 1.35
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology (2012) 1.33
Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab (2003) 1.32
Irisin: a renaissance in metabolism? Metabolism (2013) 1.32
Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev (2007) 1.31
Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes (2006) 1.29
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab (2006) 1.27
Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr (2008) 1.27
Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A (2011) 1.26
Insulin resistance and vascular dysfunction in nondiabetic Asian Indians. J Clin Endocrinol Metab (2004) 1.26
Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) (2004) 1.25
Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr (2004) 1.24
Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis (2003) 1.24
Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis (2006) 1.22
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2010) 1.21
Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr (2010) 1.20
Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs (2006) 1.20
Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer (2007) 1.20
Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am J Physiol Endocrinol Metab (2007) 1.19
Leptin in reproduction. Curr Opin Endocrinol Diabetes Obes (2007) 1.19
Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer (2008) 1.18
Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest (2015) 1.17
Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J (2011) 1.16
Helicobacter pylori induced cognitive dysfunction might be associated with falls and fractures in cirrhosis. Hepatology (2013) 1.15
Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control (2008) 1.15
Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring) (2009) 1.14
Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training. Eur J Endocrinol (2009) 1.14
Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation (2012) 1.14